Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Lenvatinib

An oral multi-tyrosine kinase inhibitor, targeting VEGF, FGF, PDGF, RET and KIT receptors, that curbs the growth of tumours and their blood vessels: approved in 2015 for differentiated thyroid cancer, it was later extended to other solid tumours. This family brings together the active ingredient, labelled standards and other impurities.

Did you know?Structural studies of the drug bound to its target revealed an unusual docking mode: it fills the ATP site with its quinoline part and anchors to a neighbouring region with a small cyclopropane ring.

LenvatinibGo to the active ingredient →
LenvatinibActive ingredientLenvatinibCat. No. P-L034-001CAS 417716-92-8
Lenvatinib-d4Isotopically labelledLenvatinib-d4Cat. No. P-L034-003CAS 2264050-65-7

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.